Suppliers and packagers for DENAVIR

DENAVIR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629	NDA AUTHORIZED GENERIC	Mylan Pharmaceuticals Inc.	0378-0896-55	1 TUBE in 1 CARTON (0378-0896-55) / 5 g in 1 TUBE	2022-11-16
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629	NDA	Mylan Pharmaceuticals Inc.	0378-9720-55	1 TUBE in 1 CARTON (0378-9720-55) / 5 g in 1 TUBE	2018-09-24

DENAVIR (penciclovir) suppliers: who makes it, where it is sourced, and what the supply chain looks like

Last updated: May 24, 2026

Suppliers for DENAVIR (penciclovir 1% cream) are best mapped at two levels: (1) the branded product manufacturer and (2) generic or contract manufacturers that supply penciclovir topical cream. DENAVIR is discontinued in several major markets, so the active supplier landscape depends on the country and whether a given SKU is branded DENAVIR or a branded/generic penciclovir cream equivalent.

What companies supply DENAVIR (penciclovir 1% cream) to pharmacies and wholesalers?

Featured snippet answer: DENAVIR supply is led by the brand’s original marketing authorization holder and its commercial manufacturers in each country; in many markets, penciclovir topical cream is supplied by generic manufacturers rather than by DENAVIR-branded sources.

Brand-holder vs. product-manufacturer split (how to map suppliers correctly)

Supply claims usually mix three different roles:

• Marketing authorization holder / MAH (owns regulatory dossier and labeling)
• Product manufacturer (makes the cream under the approved process)
• Secondary packer / distributor (packages, relabels, and releases inventory through local channels)

In drug procurement and contract manufacturing reviews, only the product manufacturer and sites that release lots determine manufacturing capability and IP/process constraints.

Market reality for DENAVIR

Penciclovir topical products have inconsistent availability by geography. In markets where DENAVIR is no longer actively distributed, “suppliers” typically become:

• Generic penciclovir 1% cream manufacturers
• Contract manufacturers producing penciclovir cream for multiple relabelers
• Parallel importers sourcing from remaining active territories

Which manufacturers make penciclovir topical cream (DENAVIR equivalents)?

Featured snippet answer: The supplier base for DENAVIR equivalents is mainly generic manufacturers that produce penciclovir 1% cream in contract arrangements, with release sites varying by country.

How supplier identification is usually done in practice

For topical creams, the fastest path to correct supplier mapping is:

1. Match the product label strength to penciclovir 1% w/w cream
2. Check the local pack for “manufactured by” and “batch released by” language
3. Crosswalk the manufacturer name to regulatory submissions or pharmacopeial quality documentation used by the country’s medicines agency
4. Validate supply continuity through lot-trace records from distributors

What this means for sourcing decisions

• If DENAVIR is discontinued in a jurisdiction, the only “DENAVIR suppliers” in procurement systems are often distributors and parallel importers.
• For formulation and IP diligence, the relevant supplier is the site making the cream, not the wholesaler.

What active ingredient (API) suppliers provide penciclovir for topical cream manufacturing?

Featured snippet answer: Penciclovir API sourcing is dominated by specialized small-molecule suppliers; topical brands and generics purchase API through contract supply and may use different API sources over time.

API sourcing impacts for penciclovir cream

API procurement matters because topical creams can be sensitive to:

• particle size and assay specs for penciclovir
• impurity profile controls
• drying and milling steps used before blending

A change in penciclovir API supplier can trigger comparability work for generics and can affect batch release acceptance, even when the finished formulation is unchanged.

How does supplier coverage differ by country for DENAVIR or penciclovir 1% cream?

Featured snippet answer: Coverage differs sharply because DENAVIR’s marketed availability varies by territory; in some markets it remains branded, in others it is replaced by generics or is absent entirely.

Country-by-country procurement pattern

• Countries with active brand distribution: fewer finished-goods suppliers, MAH-controlled distribution
• Countries with generic substitution: multiple finished-goods suppliers competing on price
• Countries with low or no availability: wholesalers list “supply” as sourcing from other regions (parallel/indirect)

What distributors are typically the “suppliers” of DENAVIR in retail and hospital channels?

Featured snippet answer: Retail pharmacy chains and hospital formularies rarely source DENAVIR directly; they purchase from local wholesalers and distributor networks that may rely on parallel imports where the brand is not routinely distributed.

Procurement implication

When a payer or tender asks for “DENAVIR suppliers,” responses often include:

• national wholesalers
• distributors handling imported finished goods
• parallel importers holding clearance for incoming lots

For contract or litigation due diligence, distributors are not the manufacturing suppliers.

What generic entry risks exist for penciclovir topical cream supply?

Featured snippet answer: The main generic entry risk is supply inconsistency rather than technical difficulty; penciclovir topical cream is a small-molecule topical product where multiple generics can enter if regulatory and manufacturing readiness are met.

Supply-chain risk drivers

• limited number of qualified sites for stable topical cream manufacture
• API supply availability and lot-to-lot impurity controls
• regulatory update requirements for manufacturing site changes

How strong is the patent/IP barrier that shapes who can supply penciclovir topical cream?

Featured snippet answer: Supplier participation is shaped by local patent landscapes and market exclusivity, but topical penciclovir generics typically face incremental formulation and process constraints rather than broad molecule blockades once primary exclusivity is exhausted.

Practical supplier consequences

• In jurisdictions where the brand or key process patents remain in force, supplier options are constrained to MAH-authorized channels or licensed generics.
• Once exclusivity ends, additional suppliers can enter, shifting competition to price and supply reliability.

Key Takeaways

• “DENAVIR suppliers” should be separated into brand marketing/distribution versus the actual cream manufacturing sites.
• In many territories, DENAVIR is replaced by generic penciclovir 1% cream, so the practical supplier universe becomes generic finished-goods manufacturers plus local import/distributor networks.
• For sourcing and diligence, the decisive suppliers are the finished-goods release manufacturers and the penciclovir API sources feeding them, not wholesalers.
• Country-specific availability drives the supplier list more than the drug name alone.

FAQs

1. Is DENAVIR still marketed in the US or EU, and who supplies it when it is discontinued?
2. How can procurement teams verify the actual manufacturer of penciclovir 1% cream from pharmacy packs?
3. Do penciclovir API suppliers change frequently for topical cream generics, and what are the batch-release implications?
4. What labeling differences help distinguish branded DENAVIR from penciclovir 1% generics?
5. Which supply-chain risks matter most for small-molecule topical creams like penciclovir?

References

1. [No sources were provided in the prompt, and no verified supplier/manufacturer names can be returned without citations.]